Teplizumab
Teplizumab is a pharmaceutical drug with 14 clinical trials. Currently 7 active trials ongoing. Historical success rate of 83.3%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
4
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
83.3%
5 of 6 finished
16.7%
1 ended early
7
trials recruiting
14
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
Long-Term Outcomes of Teplizumab in Routine Clinical Care
Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes
Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG
Clinical Trials (14)
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
Long-Term Outcomes of Teplizumab in Routine Clinical Care
Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes
Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG
Teplizumab in Pediatric Stage 2 Type 1 Diabetes
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)
A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States
Description of Patients With Type 1 Diabetes Treated With Teplizumab
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)
Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
All 14 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 14